Glycomimetics Inc. (GLYC) 7.06 $GLYC
GlycoMimetics Announces Proposed Public Offering of Common Stock
BusinessWire - Thu Jun 16, 3:01PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
GLYC: 7.06 (+0.82)
GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
BusinessWire - Fri Jun 10, 5:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
GLYC: 7.06 (+0.82)
GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
GLYC: 7.06 (+0.82)
GlycoMimetics to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City.
GLYC: 7.06 (+0.82)
Will GlycoMimetics (GLYC) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:39AM CDT
As of late, it has definitely been a great time to be an investor in GlycoMimetics, Inc. (GLYC).
GLYC: 7.06 (+0.82)
The 3 Best Developmental Stage Biotech Stocks Surging Now
Maher Syed - Zacks Investment Research - Wed May 25, 5:44PM CDT
These Biotech stocks are small now, but they look set to see significant developments in their various drug candidates.
VTAE: 10.54 (+0.15), GLYC: 7.06 (+0.82), DMTX: 7.00 (-0.46)
GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine
BusinessWire - Wed May 25, 1:00PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer. The published study details research in an in vivo model that showed the company's drug candidate, GMI-1271, a novel E-selectin antagonist, inhibits breast cancer metastasis.
GLYC: 7.06 (+0.82)
Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress
BusinessWire - Thu May 19, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia (AML) were accepted as a poster to be presented at the European Hematology Association's 21st Congress, taking place June 9-12 in Copenhagen, Denmark.
GLYC: 7.06 (+0.82)
GlycoMimetics Reports First Quarter 2016 Results
BusinessWire - Wed May 04, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2016.
GLYC: 7.06 (+0.82)
GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference
BusinessWire - Mon Apr 25, 3:30PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at "Digestive Disease Week," the annual meeting of the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. The meeting will take place May 21-24 in San Diego.
GLYC: 7.06 (+0.82)
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
BusinessWire - Mon Mar 21, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.
IMGN: 3.32 (+0.07), GLYC: 7.06 (+0.82)
GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016
BusinessWire - Thu Mar 17, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that pre-clinical research demonstrating the potential of its third drug candidate, GMI-1359, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. An oral presentation and a poster will highlight data on GMI-1359, a potent dual antagonist of both E-selectin and CXCR4, demonstrating anti-tumor activity in preclinical models of pancreatic cancer and acute myeloid leukemia (AML), respectively. In a pancreatic cancer model, GMI-1359 showed significant disruption of the tumor microenvironment and inhibited tumor metastasis. In an AML model, while either GMI-1359 or sorafenib alone reduced tumor burden, antitumor activity was significantly enhanced when GMI-1359 was given in combination with sorafenib, over either treatment alone. The AACR Annual Meeting 2016 takes place from April 16 to 20, 2016, at the Ernest N. Morial Convention Center.
GLYC: 7.06 (+0.82)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 10.28 (+0.39), PFE: 34.59 (+0.12), AKAO: 3.99 (-0.21), GLYC: 7.06 (+0.82), GSK: 42.56 (+0.80), APHB: 1.60 (-0.11), SRPT: 17.88 (+0.47), ACH: 7.87 (+0.12), AZN: 29.29 (+0.59)
Thrombosis Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s4vxk/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thrombosis Overview - Therapeutics Development - Pipeline Products for Thrombosis - Overview - Pipeline Products for Thrombosis - Comparative Analysis - Thrombosis - Therapeutics under Development by Companies - Thrombosis - Therapeutics under Investigation by Universities/Institutes - Thrombosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thrombosis - Products under Development by Companies - Thrombosis - Products under Investigation by Universities/Institutes - Thrombosis - Companies Involved in Therapeutics Development - 3SBio Inc. - Antibe Therapeutics, Inc. - Archemix Corp. - Arena Pharmaceuticals, Inc. - Armetheon, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - Cereno Scientific AB - China Biologic Products, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dyax Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - GlycoMimetics, Inc. - Green Cross Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - LG Life Science LTD. - Lipicard Technologies Limited - Merrion Pharmaceuticals Plc - Pfizer Inc. - PLx Pharma Inc. - Portola Pharmaceuticals, Inc. - Prothix BV - Sagene Pharmaceuticals, Inc. - Sanofi - SciFluor Life Sciences, LLC - The International Biotechnology Center (IBC) Generium - Zedira GmbH - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/5s4vxk/thrombosis
PTLA: 24.41 (+0.57), ARWR: 5.88 (+0.20), PFE: 34.59 (+0.12), GLYC: 7.06 (+0.82), BMY: 72.64 (+0.33), DYAX: 38.04 (-0.37), CBPO: 106.14 (+0.42), JNJ: 117.38 (+0.92), AZN: 29.29 (+0.59), PLXP: (), ARNA: 1.91 (+0.06)
Global Venous Thromboembolism Therapeutics Pipeline Review 2015
M2 - Thu Jan 07, 10:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/7p7ssr/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Venous Thromboembolism Overview - Therapeutics Development - Pipeline Products for Venous Thromboembolism - Overview - Pipeline Products for Venous Thromboembolism - Comparative Analysis - Venous Thromboembolism - Therapeutics under Development by Companies - Venous Thromboembolism - Therapeutics under Investigation by Universities/Institutes - Venous Thromboembolism - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Venous Thromboembolism - Products under Development by Companies - Venous Thromboembolism - Products under Investigation by Universities/Institutes - Venous Thromboembolism - Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/7p7ssr/venous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PTLA: 24.41 (+0.57), ISIS: 57.56 (-0.28), GLYC: 7.06 (+0.82)
Fibrosis - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qfnt7/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H2 2015" report to their offering. The report Fibrosis - Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrosis - Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned Include: - Abeome Corporation - Acceleron Pharma, Inc. - Complexa, Inc. - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Isarna Therapeutics GmbH - Lycera Corp. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Ribomic Inc. - RuiYi Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/7qfnt7/fibrosis
GLYC: 7.06 (+0.82), FGEN: 16.17 (+0.67), XOMA: 0.56 (+0.01), XLRN: 35.04 (+1.48)
GlycoMimetics Highlights Preclinical Data in Oral Presentation at ASH Meeting Demonstrating Impact of GMI-1271 on T Memory Stem Cells
BusinessWire - Mon Dec 07, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical data on its novel E-selectin antagonist drug candidate GMI-1271, shared via an oral presentation at the 57th American Society of Hematology (ASH) annual meeting, showed the compound could be used in combination with G-CSF (filgrastim) to mobilize and enrich progenitor T cells known as T memory stem (Tscm) and T central memory (Tcm) cells, which provide improved reconstitution and persistence. The company also announced that the first healthy participant has been treated with an intravenous (IV) formulation of GMI-1271 in a Phase 1, multiple-dose clinical study to evaluate the investigational drug's ability to mobilize and enrich Tscm or Tcm cells. In addition, the trial will evaluate safety and tolerability of the drug, alone and in combination with filgrastim, a treatment for neutropenia that is approved by the U.S. Food and Drug Administration (FDA).
GLYC: 7.06 (+0.82)
GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model
BusinessWire - Mon Dec 07, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical data presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting on its drug candidate GMI-1359 showed the compound enhanced the ability of chemotherapy to target and improve survival from FLT3-ITD mutated acute myeloid leukemia (AML).
GLYC: 7.06 (+0.82)
GlycoMimetics Presents at ASH Meeting First-in-Human Data Showing Favorable Safety, Metabolic and Biomarker Profiles for GMI-1271
BusinessWire - Sat Dec 05, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ:GLYC) presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting first-in-human Phase 1 results that showed a favorable safety, pharmacokinetic and biomarker profile for its drug candidate GMI-1271, which is being investigated as a treatment for acute myeloid leukemia (AML) and other blood cancers.
GLYC: 7.06 (+0.82)
GlycoMimetics Poster Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models
BusinessWire - Sat Dec 05, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that preclinical data presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, in Orlando, Florida, on its drug candidate GMI-1271 showed the compound could reverse molecular mechanisms of chemotherapy resistance seen in multiple myeloma.
GLYC: 7.06 (+0.82)
GlycoMimetics Announces Proposed Public Offering of Common Stock
BusinessWire - Thu Jun 16, 3:01PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
GLYC: 7.06 (+0.82)
GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
BusinessWire - Fri Jun 10, 5:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
GLYC: 7.06 (+0.82)
GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
GLYC: 7.06 (+0.82)
GlycoMimetics to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City.
GLYC: 7.06 (+0.82)
Will GlycoMimetics (GLYC) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:39AM CDT
As of late, it has definitely been a great time to be an investor in GlycoMimetics, Inc. (GLYC).
GLYC: 7.06 (+0.82)
The 3 Best Developmental Stage Biotech Stocks Surging Now
Maher Syed - Zacks Investment Research - Wed May 25, 5:44PM CDT
These Biotech stocks are small now, but they look set to see significant developments in their various drug candidates.
VTAE: 10.54 (+0.15), GLYC: 7.06 (+0.82), DMTX: 7.00 (-0.46)
GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine
BusinessWire - Wed May 25, 1:00PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer. The published study details research in an in vivo model that showed the company's drug candidate, GMI-1271, a novel E-selectin antagonist, inhibits breast cancer metastasis.
GLYC: 7.06 (+0.82)
Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress
BusinessWire - Thu May 19, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia (AML) were accepted as a poster to be presented at the European Hematology Association's 21st Congress, taking place June 9-12 in Copenhagen, Denmark.
GLYC: 7.06 (+0.82)
GlycoMimetics Reports First Quarter 2016 Results
BusinessWire - Wed May 04, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2016.
GLYC: 7.06 (+0.82)
GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference
BusinessWire - Mon Apr 25, 3:30PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at "Digestive Disease Week," the annual meeting of the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. The meeting will take place May 21-24 in San Diego.
GLYC: 7.06 (+0.82)
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
BusinessWire - Mon Mar 21, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.
IMGN: 3.32 (+0.07), GLYC: 7.06 (+0.82)
GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016
BusinessWire - Thu Mar 17, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that pre-clinical research demonstrating the potential of its third drug candidate, GMI-1359, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. An oral presentation and a poster will highlight data on GMI-1359, a potent dual antagonist of both E-selectin and CXCR4, demonstrating anti-tumor activity in preclinical models of pancreatic cancer and acute myeloid leukemia (AML), respectively. In a pancreatic cancer model, GMI-1359 showed significant disruption of the tumor microenvironment and inhibited tumor metastasis. In an AML model, while either GMI-1359 or sorafenib alone reduced tumor burden, antitumor activity was significantly enhanced when GMI-1359 was given in combination with sorafenib, over either treatment alone. The AACR Annual Meeting 2016 takes place from April 16 to 20, 2016, at the Ernest N. Morial Convention Center.
GLYC: 7.06 (+0.82)
Pseudomonas Aeruginosa Infections Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/npjzdg/pseudomonas) has announced the addition of the "Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pseudomonas Aeruginosa Infections Overview - Therapeutics Development - Pipeline Products for Pseudomonas Aeruginosa Infections - Overview - Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis - Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies - Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pseudomonas Aeruginosa Infections - Products under Development by Companies - Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes - Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - Aeolus Pharmaceuticals, Inc. - AlgiPharma AS - AmpliPhi Biosciences Corporation - AnGes MG, Inc. - Arch Biopartners, Inc. - Aridis Pharmaceuticals LLC - Arno Therapeutics, Inc. - AstraZeneca Plc - Biolytics Pharma - CSA Biotechnologies LLC - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - GlaxoSmithKline Plc - GlycoMimetics, Inc. - Hsiri Therapeutics, LLC - Insmed Incorporated - Lascco SA - LegoChem Biosciences, Inc - Lytix Biopharma AS - MedImmune, LLC - Nosopharm SAS - Novabiotics Limited - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Polyphor Ltd. - Sanofi - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. For more information visit http://www.researchandmarkets.com/research/np...seudomonas
INSM: 10.28 (+0.39), PFE: 34.59 (+0.12), AKAO: 3.99 (-0.21), GLYC: 7.06 (+0.82), GSK: 42.56 (+0.80), APHB: 1.60 (-0.11), SRPT: 17.88 (+0.47), ACH: 7.87 (+0.12), AZN: 29.29 (+0.59)
Thrombosis Pipeline Review, H2 2015
M2 - Mon Jan 18, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/5s4vxk/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thrombosis Overview - Therapeutics Development - Pipeline Products for Thrombosis - Overview - Pipeline Products for Thrombosis - Comparative Analysis - Thrombosis - Therapeutics under Development by Companies - Thrombosis - Therapeutics under Investigation by Universities/Institutes - Thrombosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thrombosis - Products under Development by Companies - Thrombosis - Products under Investigation by Universities/Institutes - Thrombosis - Companies Involved in Therapeutics Development - 3SBio Inc. - Antibe Therapeutics, Inc. - Archemix Corp. - Arena Pharmaceuticals, Inc. - Armetheon, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - Cereno Scientific AB - China Biologic Products, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dyax Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - GlycoMimetics, Inc. - Green Cross Corporation - Johnson & Johnson - Laboratorios Farmaceuticos Rovi, S.A. - LG Life Science LTD. - Lipicard Technologies Limited - Merrion Pharmaceuticals Plc - Pfizer Inc. - PLx Pharma Inc. - Portola Pharmaceuticals, Inc. - Prothix BV - Sagene Pharmaceuticals, Inc. - Sanofi - SciFluor Life Sciences, LLC - The International Biotechnology Center (IBC) Generium - Zedira GmbH - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/5s4vxk/thrombosis
PTLA: 24.41 (+0.57), ARWR: 5.88 (+0.20), PFE: 34.59 (+0.12), GLYC: 7.06 (+0.82), BMY: 72.64 (+0.33), DYAX: 38.04 (-0.37), CBPO: 106.14 (+0.42), JNJ: 117.38 (+0.92), AZN: 29.29 (+0.59), PLXP: (), ARNA: 1.91 (+0.06)
Global Venous Thromboembolism Therapeutics Pipeline Review 2015
M2 - Thu Jan 07, 10:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/7p7ssr/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Venous Thromboembolism Overview - Therapeutics Development - Pipeline Products for Venous Thromboembolism - Overview - Pipeline Products for Venous Thromboembolism - Comparative Analysis - Venous Thromboembolism - Therapeutics under Development by Companies - Venous Thromboembolism - Therapeutics under Investigation by Universities/Institutes - Venous Thromboembolism - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Venous Thromboembolism - Products under Development by Companies - Venous Thromboembolism - Products under Investigation by Universities/Institutes - Venous Thromboembolism - Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/7p7ssr/venous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PTLA: 24.41 (+0.57), ISIS: 57.56 (-0.28), GLYC: 7.06 (+0.82)
Fibrosis - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qfnt7/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H2 2015" report to their offering. The report Fibrosis - Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrosis - Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned Include: - Abeome Corporation - Acceleron Pharma, Inc. - Complexa, Inc. - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Isarna Therapeutics GmbH - Lycera Corp. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Ribomic Inc. - RuiYi Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/7qfnt7/fibrosis
GLYC: 7.06 (+0.82), FGEN: 16.17 (+0.67), XOMA: 0.56 (+0.01), XLRN: 35.04 (+1.48)
GlycoMimetics Highlights Preclinical Data in Oral Presentation at ASH Meeting Demonstrating Impact of GMI-1271 on T Memory Stem Cells
BusinessWire - Mon Dec 07, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical data on its novel E-selectin antagonist drug candidate GMI-1271, shared via an oral presentation at the 57th American Society of Hematology (ASH) annual meeting, showed the compound could be used in combination with G-CSF (filgrastim) to mobilize and enrich progenitor T cells known as T memory stem (Tscm) and T central memory (Tcm) cells, which provide improved reconstitution and persistence. The company also announced that the first healthy participant has been treated with an intravenous (IV) formulation of GMI-1271 in a Phase 1, multiple-dose clinical study to evaluate the investigational drug's ability to mobilize and enrich Tscm or Tcm cells. In addition, the trial will evaluate safety and tolerability of the drug, alone and in combination with filgrastim, a treatment for neutropenia that is approved by the U.S. Food and Drug Administration (FDA).
GLYC: 7.06 (+0.82)
GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model
BusinessWire - Mon Dec 07, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical data presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting on its drug candidate GMI-1359 showed the compound enhanced the ability of chemotherapy to target and improve survival from FLT3-ITD mutated acute myeloid leukemia (AML).
GLYC: 7.06 (+0.82)
GlycoMimetics Presents at ASH Meeting First-in-Human Data Showing Favorable Safety, Metabolic and Biomarker Profiles for GMI-1271
BusinessWire - Sat Dec 05, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ:GLYC) presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting first-in-human Phase 1 results that showed a favorable safety, pharmacokinetic and biomarker profile for its drug candidate GMI-1271, which is being investigated as a treatment for acute myeloid leukemia (AML) and other blood cancers.
GLYC: 7.06 (+0.82)
GlycoMimetics Poster Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models
BusinessWire - Sat Dec 05, 9:00AM CST
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that preclinical data presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, in Orlando, Florida, on its drug candidate GMI-1271 showed the compound could reverse molecular mechanisms of chemotherapy resistance seen in multiple myeloma.
GLYC: 7.06 (+0.82)
